{
    "pmcid": "11228696",
    "summary": "The review titled \"Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies\" provides a comprehensive overview of the development and application of neutralizing antibodies (NAbs) against SARS-CoV-2, with a particular focus on nanobodies (Nbs) as promising therapeutic agents. Here is a detailed summary of the key insights related to nanobodies in the context of designing SARS-CoV-2 nanobody binders:\n\n### Nanobodies Overview\n\n1. **Origin and Structure**: \n   - Nanobodies (Nbs) are derived from heavy-chain antibodies found in camelids and cartilaginous fish. They represent the smallest functional antibody fragments capable of targeting viral antigens.\n   - Nbs consist of a single variable domain (VHH in camelids and V-NAR in sharks) and are characterized by their small size, high specificity, stability, and ease of production.\n\n2. **Advantages**:\n   - **Small Size**: Their small molecular weight (<15 kDa) allows them to access epitopes that are inaccessible to conventional antibodies.\n   - **Stability**: Nbs exhibit remarkable structural stability under extreme conditions, making them suitable for long-term storage and large-scale production.\n   - **Low Immunogenicity**: Despite being non-human, VHHs have low immunogenicity due to their sequence similarity with human VH gene families.\n\n3. **Production and Engineering**:\n   - **Production**: Nbs are produced by immunizing animals (e.g., camelids) with specific antigens, followed by isolating B cells, amplifying antibody genes, and expressing them in host cells like E. coli.\n   - **Engineering**: Nbs can be engineered into multivalent or bispecific formats to enhance their binding capabilities and neutralizing potency.\n\n4. **Humanization**:\n   - Humanization is often necessary for V-NARs due to their low sequence identity with human antibodies. Techniques like CDR grafting and resurfacing are used to reduce immunogenicity.\n\n### Nanobodies in SARS-CoV-2 Neutralization\n\n1. **Mechanism of Action**:\n   - Nbs can stabilize the SARS-CoV-2 spike protein in a closed conformation, preventing its interaction with the ACE2 receptor and subsequent viral entry into host cells.\n   - They can be designed to target conserved epitopes on the spike protein, providing broad-spectrum neutralization against various SARS-CoV-2 variants.\n\n2. **Therapeutic Applications**:\n   - **Inhalation Delivery**: Nbs can be administered via inhalation, allowing direct delivery to the lungs, which is advantageous for treating respiratory infections like COVID-19.\n   - **Multivalent Formats**: Multivalent Nbs have shown enhanced neutralization capacity and stability, maintaining efficacy even after processes like nebulization and lyophilization.\n\n3. **Examples and Efficacy**:\n   - **Nb6**: Demonstrated the ability to stabilize RBDs in the down state, preventing ACE2 binding. Its trimerized form showed picomolar-range neutralization.\n   - **Nb21**: Exhibited high thermal stability and retained antiviral capacity after lyophilization and nebulization. It was effective in vitro against SARS-CoV-2.\n\n4. **Challenges and Future Prospects**:\n   - **ADE Risk**: While Nbs generally have a lower risk of antibody-dependent enhancement (ADE), careful design and testing are necessary to mitigate this risk.\n   - **Variant Resistance**: Nbs targeting conserved epitopes are promising for countering emerging variants, but ongoing surveillance and adaptation are required.\n\n### Conclusion\n\nNanobodies offer a versatile and potent approach to neutralizing SARS-CoV-2, with significant advantages in terms of production, stability, and delivery. Their ability to target conserved viral epitopes makes them promising candidates for broad-spectrum antiviral therapies. Continued research and development in nanobody engineering and humanization will enhance their therapeutic potential and application in future viral outbreaks.",
    "title": "Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review)"
}